Serge Belanger Analyst Performance

Senior Analyst at Needham & Company LLC

Serge Belanger is a stock analyst at Needham & Company LLC focused in the medical sector, covering 24 publicly traded companies. Over the past year, Serge Belanger has issued 80 stock ratings, including buy and hold recommendations. While full access to Serge Belanger's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Serge Belanger's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Ranking: Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat
Average Return: 00.00% 12-Month ROI
Success Rate: 00.00% Profitable Ratings
Total Ratings: 208 Last 11 Years
Buy Recommendations: 88.46% 184 Buy Ratings
Companies Covered: 24 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	88.5%	184 ratings
Hold	11.5%	24 ratings
Sell	0.0%	0 ratings

Out of 208 total stock ratings issued by Serge Belanger at Needham & Company LLC, the majority (88.5%) have been Buy recommendations, followed by 11.5% Hold.

Best & Worst Calls

Best Call
0000.0%
LQDA
May 2025
Subscribe to MarketBeat All Access to get analyst recommendation ROI.
Worst Call
0000.0%
CRXTQ
Mar 2022
Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	91.7% of companies on NASDAQ	22 companies
NYSE	4.2% of companies on NYSE	1 company
OTCMKTS	4.2% of companies on OTCMKTS	1 company

Serge Belanger, an analyst at Needham & Company LLC, currently covers 24 companies listed on NASDAQ, NYSE and OTCMKTS, with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 23 companies	95.8%
	Manufacturing 1 company	4.2%

Serge Belanger of Needham & Company LLC specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 11 companies	45.8%
MED - DRUGS 9 companies	37.5%
MED PRODUCTS 2 companies	8.3%
PHARMACEUTICAL PREPARATIONS 1 company	4.2%
MED - GENERIC DRG 1 company	4.2%

About Serge Belanger

Serge Belanger joined Needham & Company in 2009, where he covers the Biotechnology sector. Prior to Needham, Serge worked as a research associate at Fulcrum Global Partners and Susquehanna International Group covering the biotech and specialty pharma healthcare sectors. Previously, Serge was part of Adolor Corporation, a biopharmaceutical company, as a senior research scientist, where he was involved with the discovery and development of novel opioid receptor targeted molecules and non-opioid pain therapeutics. Serge graduated from McGill University with a BSc, Biochemistry/Pharmacology, and an MSc, Pharmacology and Therapeutics. He obtained his MBA in Finance from the Stern School of Business at New York University.

Follow on LinkedIn

Timeframe

Start Date

End Date

Rating

12-Month ROIAll ROI

Export

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating
MANE Veradermics	7/15/2026	Boost Price Target	$128.74	$164.00	Buy
VRDN Viridian Therapeutics	6/29/2026	Reiterated Rating	$17.90	$32.00	Buy
CYTK Cytokinetics	6/17/2026	Reiterated Rating	$75.21	$102.00	Buy
HRTX Heron Therapeutics	6/2/2026	Downgrade	$0.45		Hold
MANE Veradermics	6/2/2026	Initiated Coverage	$101.96	$136.00	Buy
OCS Oculis	6/1/2026	Lower Price Target	$22.70	$38.00	Buy
TRVI Trevi Therapeutics	5/20/2026	Reiterated Rating	$13.77	$23.00	Buy
MLTX MoonLake Immunotherapeutics	5/12/2026	Boost Price Target	$18.84	$30.00	Buy
OCS Oculis	5/12/2026	Boost Price Target	$30.40	$46.00	Buy
LQDA Liquidia	5/11/2026	Boost Price Target	$52.61	$70.00	Buy
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
XENE Xenon Pharmaceuticals	5/8/2026	Lower Price Target	$56.00	$78.00	Buy
AMPH Amphastar Pharmaceuticals	5/8/2026	Reiterated Rating	$24.03		Hold
ARQT Arcutis Biotherapeutics	5/7/2026	Reiterated Rating	$24.17	$36.00	Buy
TRVI Trevi Therapeutics	5/6/2026	Lower Price Target	$14.66	$23.00	Buy
BCRX BioCryst Pharmaceuticals	5/6/2026	Lower Price Target	$8.86	$16.00	Buy
VRDN Viridian Therapeutics	5/5/2026	Reiterated Rating	$18.77	$32.00	Buy
OCUL Ocular Therapeutix	5/5/2026	Reiterated Rating	$9.71	$18.00	Buy
CYTK Cytokinetics	5/5/2026	Boost Price Target	$77.20	$102.00	Buy
ESPR Esperion Therapeutics	5/4/2026	Downgrade	$3.12		Hold
PCRX Pacira BioSciences	5/1/2026	Boost Price Target	$25.49	$32.00	Buy
KALV KalVista Pharmaceuticals	4/30/2026	Downgrade	$26.66		Hold
CRMD CorMedix	4/27/2026	Boost Price Target	$7.54	$15.00	Buy
VRDN Viridian Therapeutics	3/30/2026	Lower Price Target	$18.52	$32.00	Buy
KALV KalVista Pharmaceuticals	3/25/2026	Boost Price Target	$17.14	$36.00	Buy
COLL Collegium Pharmaceutical	3/19/2026	Reiterated Rating	$36.30	$56.00	Buy
TRVI Trevi Therapeutics	3/18/2026	Boost Price Target	$11.19	$24.00	Buy
XENE Xenon Pharmaceuticals	3/9/2026	Boost Price Target	$61.46	$80.00	Buy
LQDA Liquidia	3/5/2026	Boost Price Target	$34.52	$54.00	Buy
CRMD CorMedix	3/5/2026	Lower Price Target	$6.30	$14.00	Buy
OCS Oculis	3/4/2026	Boost Price Target	$27.57	$40.00	Buy
ESPR Esperion Therapeutics	3/3/2026	Boost Price Target	$2.94	$5.00	Buy
AMPH Amphastar Pharmaceuticals	2/27/2026	Lower Price Target	$26.49	$30.00	Buy
XENE Xenon Pharmaceuticals	2/27/2026	Boost Price Target	$42.23	$58.00	Buy
ARQT Arcutis Biotherapeutics	2/26/2026	Boost Price Target	$27.01	$36.00	Buy
COLL Collegium Pharmaceutical	2/26/2026	Lower Price Target	$44.01	$54.00	Buy
CYTK Cytokinetics	2/25/2026	Boost Price Target	$70.10	$85.00	Buy
LQDA Liquidia	2/25/2026	Reiterated Rating	$30.16	$52.00	Buy
MLTX MoonLake Immunotherapeutics	2/23/2026	Boost Price Target	$18.68	$25.00	Buy
OCUL Ocular Therapeutix	2/20/2026	Lower Price Target	$7.03	$18.00	Buy
NAMS NewAmsterdam Pharma	2/18/2026	Boost Price Target	$36.41	$48.00	Buy
Ticker Revealed: Pre-IPO Access to "Next Elon Musk" Company (Ad) We’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it. 👉 Unlock the ticker now and get it completely free.
VRDN Viridian Therapeutics	2/4/2026	Reiterated Rating	$31.90	$42.00	Buy
ARQT Arcutis Biotherapeutics	1/26/2026	Boost Price Target	$26.29	$31.00	Buy
PCRX Pacira BioSciences	1/9/2026	Reiterated Rating	$26.02	$30.00	Buy
CRMD CorMedix	1/8/2026	Lower Price Target	$7.51	$15.00	Buy
COLL Collegium Pharmaceutical	1/8/2026	Boost Price Target	$48.78	$56.00	Buy
KALV KalVista Pharmaceuticals	1/6/2026	Boost Price Target	$15.66	$32.00	Buy
EOLS Evolus	12/24/2025	Reiterated Rating	$6.81		Hold
VRDN Viridian Therapeutics	12/23/2025	Boost Price Target	$32.47	$42.00	Buy
CYTK Cytokinetics	12/22/2025	Boost Price Target	$62.72	$84.00	Buy
CYTK Cytokinetics	12/12/2025	Reiterated Rating	$60.77	$72.00	Buy
OCUL Ocular Therapeutix	12/8/2025	Reiterated Rating	$15.95	$20.00	Buy
KALV KalVista Pharmaceuticals	12/4/2025	Reiterated Rating	$14.66	$28.00	Buy
CLSD Clearside Biomedical	11/18/2025	Reiterated Rating	$3.32		Hold
CRMD CorMedix	11/12/2025	Lower Price Target	$11.17	$16.00	Buy
OCS Oculis	11/11/2025	Reiterated Rating	$19.42	$36.00	Buy
AMPH Amphastar Pharmaceuticals	11/7/2025	Lower Price Target	$24.23	$34.00	Buy
NAMS NewAmsterdam Pharma	11/5/2025	Boost Price Target	$39.84	$46.00	Buy
BCRX BioCryst Pharmaceuticals	11/4/2025	Lower Price Target	$6.86	$18.00	Buy
LQDA Liquidia	11/4/2025	Boost Price Target	$25.22	$52.00	Buy
XENE Xenon Pharmaceuticals	11/4/2025	Reiterated Rating	$41.12	$55.00	Buy
COLL Collegium Pharmaceutical	10/28/2025	Reiterated Rating	$34.81	$46.00	Buy
ARQT Arcutis Biotherapeutics	10/28/2025	Boost Price Target	$24.95	$30.00	Buy
AMPH Amphastar Pharmaceuticals	10/22/2025	Reiterated Rating	$24.26	$36.00	Buy
BCRX BioCryst Pharmaceuticals	10/15/2025	Boost Price Target	$6.42	$20.00	Buy
OMER Omeros	10/15/2025	Reiterated Rating	$10.94		Hold
OCUL Ocular Therapeutix	10/1/2025	Boost Price Target	$11.11	$20.00	Buy
MLTX MoonLake Immunotherapeutics	9/30/2025	Lower Price Target	$6.24	$20.00	Buy
KALV KalVista Pharmaceuticals	9/12/2025	Reiterated Rating	$13.60	$28.00	Buy
CYTK Cytokinetics	9/2/2025	Reiterated Rating	$35.33	$72.00	Buy
OCS Oculis	8/27/2025	Initiated Coverage	$17.53	$36.00	Buy
OMER Omeros	8/15/2025	Reiterated Rating	$4.12		Hold
AMPH Amphastar Pharmaceuticals	8/12/2025	Upgrade	$27.36	$36.00	Buy
LQDA Liquidia	8/12/2025	Boost Price Target	$24.10	$36.00	Buy
TRVI Trevi Therapeutics	8/8/2025	Lower Price Target	$7.30	$22.00	Buy
HRTX Heron Therapeutics	8/8/2025	Lower Price Target	$1.33	$3.00	Buy
ARQT Arcutis Biotherapeutics	8/7/2025	Boost Price Target	$15.36	$22.00	Buy
VRDN Viridian Therapeutics	8/6/2025	Lower Price Target	$17.22	$34.00	Buy
EOLS Evolus	8/6/2025	Reiterated Rating	$8.91	$22.00	Hold
OCUL Ocular Therapeutix	8/5/2025	Boost Price Target	$12.00	$15.00	Buy
BCRX BioCryst Pharmaceuticals	8/4/2025	Reiterated Rating	$8.73	$17.00	Buy
CLSD Clearside Biomedical	7/17/2025	Downgrade	$9.12	$45.00	Hold
BCRX BioCryst Pharmaceuticals	6/25/2025	Reiterated Rating	$9.78	$17.00	Buy
CRMD CorMedix	6/24/2025	Boost Price Target	$16.56	$20.00	Buy
NAMS NewAmsterdam Pharma	6/12/2025	Reiterated Rating	$20.50	$40.00	Buy
LQDA Liquidia	5/28/2025	Reiterated Rating	$15.60	$25.00	Buy
ARQT Arcutis Biotherapeutics	5/23/2025	Reiterated Rating	$13.66	$20.00	Buy
LQDA Liquidia	5/21/2025	Reiterated Rating	$17.02	$25.00	Buy
TRVI Trevi Therapeutics	5/20/2025	Reiterated Rating	$6.49	$24.00	Buy
VRDN Viridian Therapeutics	5/20/2025	Reiterated Rating	$13.25	$36.00	Buy
OMER Omeros	5/16/2025	Reiterated Rating	$3.95		Hold
SPCX Warning - and Worst News for Stocks in 50 Years (Ad) Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in 50 years - and it has nothing to do with a single stock. According to multiple Wall Street banks, a coming crisis could keep your portfolio in the red for 10 years or longer. Keith Kaplan, CEO of TradeSmith, is sharing what you can do to protect your wealth before it hits. Learn how to prepare your portfolio for what's coming next
CLSD Clearside Biomedical	5/15/2025	Lower Price Target	$12.81	$45.00	Buy
CYTK Cytokinetics	5/14/2025	Reiterated Rating	$30.61	$72.00	Buy
VRCA Verrica Pharmaceuticals	5/14/2025	Reiterated Rating	$0.50		Hold
XENE Xenon Pharmaceuticals	5/13/2025	Lower Price Target	$35.85	$55.00	Buy
MLTX MoonLake Immunotherapeutics	5/13/2025	Reiterated Rating	$40.18	$66.00	Buy
LQDA Liquidia	5/12/2025	Reiterated Rating	$15.93	$25.00	Buy
PCRX Pacira BioSciences	5/9/2025	Lower Price Target	$24.90	$30.00	Buy
EOLS Evolus	5/8/2025	Reiterated Rating	$11.80	$22.00	Buy
NAMS NewAmsterdam Pharma	5/8/2025	Lower Price Target	$19.50	$40.00	Buy
VRDN Viridian Therapeutics	5/7/2025	Lower Price Target	$12.03	$36.00	Buy
CRMD CorMedix	5/7/2025	Boost Price Target	$11.16	$15.00	Buy
ESPR Esperion Therapeutics	5/7/2025	Lower Price Target	$0.98	$4.00	Buy
BCRX BioCryst Pharmaceuticals	5/6/2025	Boost Price Target	$11.03	$17.00	Buy
CYTK Cytokinetics	5/2/2025	Reiterated Rating	$42.92	$72.00	Buy
MLTX MoonLake Immunotherapeutics	4/30/2025	Reiterated Rating	$40.18	$66.00	Buy
ESPR Esperion Therapeutics	4/25/2025	Reiterated Rating	$0.88	$5.00	Buy
HRTX Heron Therapeutics	4/11/2025	Reiterated Rating	$1.82	$4.00	Buy
BCRX BioCryst Pharmaceuticals	4/10/2025	Reiterated Rating	$6.77	$15.00	Buy
LQDA Liquidia	4/10/2025	Reiterated Rating	$12.77	$25.00	Buy
AMPH Amphastar Pharmaceuticals	4/10/2025	Reiterated Rating	$25.23		Hold
ARQT Arcutis Biotherapeutics	4/9/2025	Reiterated Rating	$13.29	$20.00	Buy
VRCA Verrica Pharmaceuticals	4/9/2025	Reiterated Rating	$0.58		Hold
EOLS Evolus	4/9/2025	Reiterated Rating	$9.36	$22.00	Buy
CRMD CorMedix	4/9/2025	Reiterated Rating	$6.79	$12.00	Buy
KALV KalVista Pharmaceuticals	4/8/2025	Reiterated Rating	$11.50	$28.00	Buy
TRVI Trevi Therapeutics	4/8/2025	Reiterated Rating	$5.78	$24.00	Buy
CYTK Cytokinetics	4/8/2025	Reiterated Rating	$35.99	$72.00	Buy
ESPR Esperion Therapeutics	4/8/2025	Reiterated Rating	$1.20	$5.00	Buy
CLSD Clearside Biomedical	4/8/2025	Reiterated Rating	$12.68	$60.00	Buy
NAMS NewAmsterdam Pharma	4/8/2025	Reiterated Rating	$15.86	$42.00	Buy
PCRX Pacira BioSciences	4/8/2025	Reiterated Rating	$22.91	$32.00	Buy
ARQT Arcutis Biotherapeutics	4/3/2025	Reiterated Rating	$16.60	$20.00	Buy
OMER Omeros	4/1/2025	Reiterated Rating	$8.27		Hold
CLSD Clearside Biomedical	3/28/2025	Lower Price Target	$15.45	$60.00	Buy
CRMD CorMedix	3/26/2025	Lower Price Target	$7.34	$12.00	Buy
KALV KalVista Pharmaceuticals	3/26/2025	Reiterated Rating	$12.07	$28.00	Buy
LQDA Liquidia	3/20/2025	Boost Price Target	$14.92	$25.00	Buy
TRVI Trevi Therapeutics	3/19/2025	Lower Price Target	$6.56	$24.00	Buy
KALV KalVista Pharmaceuticals	3/13/2025	Reiterated Rating	$12.45	$28.00	Buy
OCUL Ocular Therapeutix	3/11/2025	Initiated Coverage	$7.65	$15.00	Buy
TRVI Trevi Therapeutics	3/10/2025	Boost Price Target	$4.30	$25.00	Buy
CLSD Clearside Biomedical	3/6/2025	Reiterated Rating	$14.40	$90.00	Buy
EOLS Evolus	3/5/2025	Reiterated Rating	$14.35	$22.00	Buy
PCRX Pacira BioSciences	2/28/2025	Boost Price Target	$25.38	$32.00	Buy
HRTX Heron Therapeutics	2/28/2025	Reiterated Rating	$2.05	$4.00	Buy
MLTX MoonLake Immunotherapeutics	2/27/2025	Boost Price Target	$42.37	$66.00	Buy
ARQT Arcutis Biotherapeutics	2/26/2025	Reiterated Rating	$12.20	$20.00	Buy
CYTK Cytokinetics	2/6/2025	Reiterated Rating	$46.44	$72.00	Buy
EOLS Evolus	1/21/2025	Reiterated Rating	$13.87	$22.00	Buy
OMER Omeros	1/17/2025	Reiterated Rating	$9.18		Hold
The REAL Reason Trump is Invading Iran (Ad) For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason. Click here to find out what it is.
BCRX BioCryst Pharmaceuticals	1/13/2025	Boost Price Target	$7.67	$15.00	Buy
PCRX Pacira BioSciences	1/13/2025	Boost Price Target	$20.64	$30.00	Buy

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Top Stock Recommendations by Brokerage

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Serge Belanger Analyst Performance

Ratings Distribution

Best & Worst Calls

Exchange Coverage

Coverage Focus

Coverage Industries

About Serge Belanger

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Top Stock Recommendations by Brokerage

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Serge Belanger Analyst Performance

Analyst Rankings, Coverage, and Performance Statistics

Ratings Distribution

Best & Worst Calls

Exchange Coverage

Coverage Focus

Coverage Industries

About Serge Belanger

Serge Belanger's Ratings History at Needham & Company LLC

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Top Stock Recommendations by Brokerage

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools